

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 April 2024 (25.04.2024)



(10) International Publication Number
WO 2024/086579 A3

(51) International Patent Classification:

A61K 31/522 (2006.01) A61K 9/00 (2006.01)
A61K 31/5377 (2006.01) A61P 1/14 (2006.01)
C07D 473/32 (2006.01) A61P 31/04 (2006.01)

(21) International Application Number:

PCT/US2023/077091

(22) International Filing Date:

17 October 2023 (17.10.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/416,840 17 October 2022 (17.10.2022) US
63/495,243 10 April 2023 (10.04.2023) US
63/538,981 18 September 2023 (18.09.2023) US

(71) Applicant: ACURX PHARMACEUTICALS, INC.

[US/US]: 259 Liberty Ave., Staten island, New York 10305 (US).

(72) Inventors: **GARY, Kevin**; 311 W. 24TH Street, Houston, Texas 77018 (US). **BASSÈRES, Eugénie**; 606 Harold Street, Apt. #4, Houston, Texas 77006 (US).

(74) Agent: **LENTZ, Shannon**; Crowell & Moring LLP, 1001 Pennsylvania Ave NW, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: COMPOUNDS AND METHODS FOR IMPROVING HEALTH




Figure 1A

(57) Abstract: The technical field relates to methods for promoting gut microbiome health using low G+C Directed (LDN) analogs. More particularly, the technical field relates to methods of using LDN analogs as inhibitors of DNA Polymerase III (DNA pol III) enzyme to selectively reduce physiologically harmful Gram-positive bacteria with a genome having low amounts of Guanine and Cytosine (rather the genomes comprise a greater amount of adenine and thymine/uracil nucleotides) in the gut microbiome while simultaneously maintaining or increasing the proportions of beneficial microflora.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

30 May 2024 (30.05.2024)